Clinical Trial

Safety and Efficacy of Pucotenlimab in pLECC

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Lymphoepithelioma-like carcinoma (LELC) in children is a rare epithelial malignant tumor. Regarding pediatric lymphoepithelioma-like carcinoma (pLELC), its clinicopathological features, prognosis, and molecular characteristics remain unknown. In preclinical studies, this study aims to explore the safety and efficacy of the PD-1 monoclonal antibody pucotenlimab combined with the chemotherapy regimen of gemcitabine and cisplatin as the first-line treatment for lymphoepithelioma-like carcinoma in children and adolescents.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-05-05.
Trial Details
NCT Number NCT06969534
Lead Sponsor Sun Yat-sen University
Conditions Lymphoepithelioma-like Carcinoma, Lymphoepithelioma, Carcinoma
Enrollment 33 participants
Start Date 2025-05-15
Primary Completion 2027-12-30 (estimated)
Study Completion 2028-12-30 (estimated)
Updated on ClinicalTrials.gov 2025-05-15